GSA Capital Partners LLP boosted its holdings in shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 12.7% in the first quarter, Holdings Channel reports. The institutional investor owned 460,567 shares of the specialty pharmaceutical company’s stock after purchasing an additional 51,900 shares during the quarter. GSA Capital Partners LLP’s holdings in BioDelivery Sciences International were worth $1,036,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Royce & Associates LP increased its holdings in shares of BioDelivery Sciences International by 43.0% during the 4th quarter. Royce & Associates LP now owns 1,848,600 shares of the specialty pharmaceutical company’s stock valued at $5,453,000 after purchasing an additional 555,800 shares in the last quarter. Broadfin Capital LLC increased its holdings in BioDelivery Sciences International by 5.1% in the 4th quarter. Broadfin Capital LLC now owns 4,634,119 shares of the specialty pharmaceutical company’s stock worth $13,671,000 after acquiring an additional 223,253 shares in the last quarter. BlueCrest Capital Management Ltd acquired a new stake in BioDelivery Sciences International during the 4th quarter worth $201,000. Goldman Sachs Group Inc. acquired a new stake in BioDelivery Sciences International during the 4th quarter worth $223,000. Finally, Wells Fargo & Company MN boosted its stake in BioDelivery Sciences International by 88.9% during the 4th quarter. Wells Fargo & Company MN now owns 67,081 shares of the specialty pharmaceutical company’s stock worth $198,000 after purchasing an additional 31,575 shares during the last quarter. 46.14% of the stock is owned by institutional investors.

BioDelivery Sciences International opened at $2.90 on Wednesday, Marketbeat Ratings reports. The stock has a market cap of $171.89 million, a P/E ratio of -7.44 and a beta of 0.53. BioDelivery Sciences International, Inc. has a 52 week low of $1.70 and a 52 week high of $3.60. The company has a debt-to-equity ratio of 35.82, a current ratio of 1.40 and a quick ratio of 1.13.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Thursday, May 10th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03. The firm had revenue of $11.28 million for the quarter, compared to analyst estimates of $10.77 million. BioDelivery Sciences International had a negative return on equity of 388.58% and a negative net margin of 122.75%. sell-side analysts forecast that BioDelivery Sciences International, Inc. will post -0.68 earnings per share for the current year.

In other news, Director Mark A. Sirgo sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 10th. The stock was sold at an average price of $2.06, for a total value of $206,000.00. Following the completion of the sale, the director now directly owns 2,585,966 shares in the company, valued at approximately $5,327,089.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Paolantonio Ernest Robert De sold 64,155 shares of the business’s stock in a transaction that occurred on Friday, April 6th. The shares were sold at an average price of $2.09, for a total value of $134,083.95. Following the transaction, the chief financial officer now owns 97,731 shares of the company’s stock, valued at approximately $204,257.79. The disclosure for this sale can be found here. Company insiders own 7.73% of the company’s stock.

Several research analysts have recently weighed in on BDSI shares. HC Wainwright set a $4.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Friday, April 13th. Cantor Fitzgerald reiterated a “buy” rating and set a $5.00 price target on shares of BioDelivery Sciences International in a research note on Thursday, March 15th. Roth Capital set a $4.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Friday, May 11th. Zacks Investment Research upgraded shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. Finally, ValuEngine raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $4.07.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Want to see what other hedge funds are holding BDSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.